Reported cash
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
Price chart
What changed?
No verified development in tracked sources.
Upcoming catalysts
Next verified event · Clinical readout window
BMN 333 · clinical data · 2027
Announced Nov 2, 2026 · Announced window
Official announcementSource wording
•The Phase 2/3 study for BMN 333, BioMarin's long-acting C-type natriuretic peptide (CNP) for achondroplasia, continues to enroll on track. Dose-response data from this study is expected in 2027.
Clinical readout window
BMN 440 · 2027
hypophosphatasia (HPP)
Phase 1/2a
Announced Nov 2, 2026 · Announced window
Official announcementSource wording
BioMarin is accelerating innovation by expanding its pipeline through business development. Four transactions in 2026 have added development programs from preclinical through Phase 3: ◦BMN 450 (HM15421/GC1134A) is an investigational long-acting enzyme replacement therapy (ERT) that has the potential to be the first subcutaneous ERT for Fabry disease. Now in a global Phase 1/2 clinical study, it could extend BioMarin’s reach beyond patients with genetic variants amenable to GALAFOLD®. ◦BMN 440 (ALE1) for hypophosphatasia (HPP) is a potential first-in-class oral therapy for HPP. The Phase 1/2a study in healthy volunteers and adults with HPP is ongoing, with data expected in 2027. ◦BMN 430 for ReNU syndrome has the potential to be a first-in-disease antisense oligonucleotide (A
FDA target date
VOXZOGO · achondroplasia · February 28, 2027
achondroplasia
Announced Nov 2, 2026
Official announcementSource wording
•BioMarin’s application for full approval of VOXZOGO in children with achondroplasia is under review by the FDA, with a PDUFA target action date of February 28, 2027. The application includes long-term safety and efficacy data, such as final adult height and clinical outcomes beyond linear growth.
FDA target date
VOXZOGO · HCH · May 30, 2027
HCH
Announced Nov 2, 2026
Official announcementSource wording
•Today, BioMarin announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA target action date of May 30, 2027 for its supplemental NDA to expand the use of VOXZOGO for the treatment of HCH, the first potential targeted therapy for the condition. BioMarin also announced today that the European Medicines Agency (EMA) validated its submission for the approval of VOXZOGO to treat HCH.
Clinical readout window
BMN 820 · clinical data · 2028
focal segmental glomerulosclerosis (FSGS)
Phase 3
Announced Nov 2, 2026 · Announced window
Official announcementSource wording
◦BMN 820 (DMX-200) for focal segmental glomerulosclerosis (FSGS) is a first-in-class oral CCR2 inhibitor for which BioMarin holds exclusive U.S. commercialization rights. The Phase 3 ACTION 3 trial is fully enrolled, with pivotal data expected in 2028.
Drug pipeline
0 programs · 0 verified studies
No verified studies linked yet.
171 unverified sponsor matches remain unlinked.
Verified timeline
0 recordsNo verified developments in tracked sources.